Systemic sclerosis & Raynaud's
Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review
Study context
- Population
- Published treatment studies of localized scleroderma (LS)/morphea168 studies
- Outcome
- Types of outcomes and measures (clinician-, patient- and caregiver-reported) used in published treatment studies of LS
Methodological detailsspecial focus on pediatrics, Some studies only vaguely reported the measures used; the review yielded a low number of clinical trials
- Special focus on pediatrics
- Some studies only vaguely reported the measures used; the review yielded a low number of clinical trials
Main finding
As reported in the abstract
Outcomes and measures used in LS treatment studies
- Most common outcomes: cutaneous disease activity and damage, measured via clinician-reported assessments
- Most frequently cited measure: Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)
- Few patient-reported outcome measures (PROMs) used
Original publication
Endpoints and outcomes for localized scleroderma/morphea: a scoping literature review. Pediatr Rheumatol Online J. Published 21 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →